# Home versus Office blood pressure MEasurements: Reduction of Unnecessary treatment Study

Submission date Recruitment status Prospectively registered 19/10/2006 No longer recruiting [ ] Protocol Statistical analysis plan Overall study status Registration date 06/12/2006 Completed [X] Results Individual participant data Last Edited Condition category Circulatory System 25/10/2022

# Plain English summary of protocol

Not provided at time of registration

# Contact information

### Type(s)

Scientific

#### Contact name

Prof Peter de Leeuw

#### Contact details

P Debyelaan 25 5800 Maastricht Netherlands 6229 AZ

Ple@sint.azm.nl

# Additional identifiers

**EudraCT/CTIS number** Nil known

IRAS number

ClinicalTrials.gov number

Nil known

# Secondary identifying numbers

Nil known

# Study information

#### Scientific Title

Home versus Office blood pressure MEasurements: Reduction of Unnecessary treatment Study

#### Acronym

**HOMERUS** 

#### Study objectives

Antihypertensive treatment based on self measured blood pressure values may lead to less use of drugs without leading to worse blood pressure control or more target organ damage as compared to patients who are treated based on conventional office blood pressure measurement.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Informed consent, in accordance with the declaration of Helsinki, has been obtained from all patients prior to entering the study. Good clinical practice is maintained and the study protocol has been approved by the ethical committees of all participating centres before inclusion of patients into the study.

#### Study design

A multicentre prospective randomised clinical trial with a parallel group design. Patients are followed-up for a period of one year.

## Primary study design

Interventional

# Secondary study design

Randomised controlled trial

## Study setting(s)

Other

## Study type(s)

Treatment

#### Participant information sheet

## Health condition(s) or problem(s) studied

Hypertension

#### Interventions

Group one: patients receive antihypertensive treatment on the basis of self blood pressure measurement.

Group two: patients are treated based on conventional office blood pressure measurement.

#### **Intervention Type**

Other

#### Phase

**Not Specified** 

#### Primary outcome measure

- 1. Blood pressure value (conventional office blood pressure and 24 hour ambulatory blood pressure)
- 2. Target organ damage (kidney, heart)
- 3. Cost and number of antihypertensive drugs

#### Secondary outcome measures

- 1. Compliance with treatment
- 2. Quality of life

#### Overall study start date

01/10/2001

#### Completion date

01/10/2004

# **Eligibility**

#### Key inclusion criteria

- 1. Males and females aged 18 years and above
- 2. Average blood pressure between 139 and 200 mmHg for systolic or between 90 and 120 mmHg for diastolic blood pressure
- 3. Participating subjects are physically and mentally able to measure their own blood pressure
- 4. Subjects are willing to remain in follow-up during a period of one year
- 5. Signed informed consent

#### Participant type(s)

**Patient** 

#### Age group

Adult

#### Lower age limit

18 Years

#### Sex

Both

## Target number of participants

430 (216 self-measured pressures, 214 office pressures)

#### Key exclusion criteria

- 1. The presence of clinically manifest cardiovascular events (angina pectoris, heart failure, hypertensive encephalopathy, or prior myocardial infarction or cerebrovascular accident)
- 2. Severe non-cardiovascular disease (e.g. malignancy), which will interfere with adequate follow up
- 3. Allergy or contra-indications for the antihypertensive drugs used in this study
- 4. Serum creatinine above 150 micromol/l
- 5. Clinically significant orthostatic hypotension (a drop in systolic blood pressure of more than 20 mmHg upon standing)
- 6. Blood pressure devices

#### Date of first enrolment

01/10/2001

#### Date of final enrolment

01/10/2004

# Locations

#### Countries of recruitment

Netherlands

# Study participating centre

P Debyelaan 25

Maastricht Netherlands 6229 AZ

# Sponsor information

#### Organisation

The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)

## Sponsor details

PO Box 93245 Den Haag Netherlands 2509 AE

info@zonmw.nl

# Sponsor type

Research organisation

#### Website

http://www.zonmw.nl/nl/home/contact.html

#### ROR

https://ror.org/01yaj9a77

# Funder(s)

#### Funder type

Research organisation

#### **Funder Name**

The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands) (ref: 945-01-043)

# **Results and Publications**

# Publication and dissemination plan

Not provided at time of registration

#### Intention to publish date

# Individual participant data (IPD) sharing plan

Not provided at time of registration

# IPD sharing plan summary

Not provided at time of registration

# **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Other publications		01/08/2003		Yes	No
Other publications		01/08/2005		Yes	No
Other publications		01/08/2006		Yes	No
Results article		01/12/2007		Yes	No
Results article		01/12/2007		Yes	No